At PolTREG, we are very excited to announce we have received a patent in the US protecting an important part of our business: the manufacturing of T-regulatory cells (T-regs) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. 

“The decision by the US Patent and Trademark Office (USPTO) complements our large intellectual property portfolio in the US and EU. It paves the way for rapid commercialization of our cell therapies,” said PolTREG CEO Prof Piotr Trzonkowski.

Many of PolTREG’s patents are primary in the field, given that our team performed first-in-human trials with Treg cell therapies in graft-vs-host disease in 2007-2009. 

We now have 17 years’ experience with patients. We have so far successfully treated 27 Type-1 Diabetes patients commercially under a local hospital exemption program.